October 27th in Seattle: Groundbreaking Symposium on Psychedelics & End-of-Life Care

Press Release October 18, 2017
Media Contact

Contact:
Jag Davies, 212-613-8035

Exciting new research is revealing that psychedelic drugs, such as psilocybin, LSD and MDMA may offer significant benefit for patients struggling at the end of life and those beset by major depression and treatment-resistant post-traumatic stress.

On Friday, October 27 a first-of-its-kind symposium will be held at the University of Washington School of Law, bringing together doctors, scientific researchers, attorneys and ethicists. The speakers will consider the medical, legal and ethical implications of emerging research on psychedelics and end-of-life care. They will also center the discussion around the shifting policies and priorities of our state and federal drug laws.

This symposium is co-organized by the Drug Policy Alliance, the End of Life Liberty Project, and the Center for Law, Science and Global Health at the University of Washington School of Law.

Speakers include MAPS Executive Director Rick Doblin, End of Life Liberty Project Executive Director Kathryn Tucker, former DPA Executive Director Ethan Nadelmann, professor and author Ingrid Walker, Washington State Representative Roger Goodman, and many more.

Psychedelic Medicine: New Frontiers in Palliative Care
When: Friday, October 27, 8am – 5pm
Where: University of Washington School of Law, William H. Gates Hall, Seattle

The symposium’s agenda includes the following panels and presentations:

Those planning to attend the symposium are encouraged to register immediately, as space is limited.

en_USEnglish